Friday 10th December 2021
|Text too small?|
EBOS Group Limited (“EBOS”) is pleased to announce the successful completion of the fully underwritten placement ("Placement") of approximately 19.5 million new fully paid ordinary shares (“New Shares”), raising approximately NZ$674 million / A$642 million to partly fund the acquisition of LifeHealthcare.
The issue price of NZ$34.50 represented a 5.5% discount to the closing price on NZX of NZ$36.50 per share, as at 8 December 2021. The Placement was strongly supported by a broad range of existing and new investors across New Zealand, Australia and offshore. Eligible shareholders who bid for an amount less than or equal to their ‘pro rata’ share of New Shares under the Placement and Retail Offer have been allocated their full bid on a best endeavours basis.
John Cullity, EBOS Chief Executive Officer, said: “We are very encouraged by the strong support from investors for the Placement and in particular, the level of support from our existing shareholders. We are also pleased to have the opportunity to welcome new high-quality investors to the register. The acquisition of LifeHealthcare accelerates EBOS’ medical devices strategy and creates a platform for EBOS to capitalise on additional future growth opportunities. We look forward to completion and the integration of LifeHealthcare into our existing institutional healthcare division.”
EBOS Chair, Liz Coutts added, “It is very pleasing to see the support EBOS has received for this transaction. I encourage our retail shareholders in New Zealand and Australia to read and consider the retail offer booklet that will be distributed to you in the coming days. We look forward to continuing to drive future growth through our disciplined investment strategy to create further shareholder value.”
EBOS’ ordinary shares will recommence trading upon market open today. Settlement of the Placement is expected to occur on Tuesday, 14 December and Wednesday, 15 December for the ASX and NZX respectively, with allotment of all New Shares (representing approximately 11.9% of EBOS’ existing shares on issue) on Wednesday, 15 December. The New Shares issued under the Placement will rank equally with EBOS existing ordinary shares on issue.
As previously announced, EBOS intends to conduct a non-underwritten retail offer to eligible existing shareholders to raise up to NZ$105 million (A$100 million ), with the ability to accept oversubscriptions at EBOS’ discretion (Retail Offer).
Full details of the Retail Offer will be set out in the Retail Offer Booklet, which will be released to the NZX and ASX, and sent to eligible shareholders on or about Wednesday, 15 December 2021. The closing date for applications by eligible shareholders is Monday, 17 January 2022.
Please see the link below for details
No comments yet
4th July 2022 Morning Report
BIF - Acquires shares in Hot Lime Labs
RUA - Cann Group granted TGA GMP for Mildura facility
AFI - Invitation to Results Webcast
PFI Share Buyback Programme to Pause
Greenfern Industries Limited ("GFI") - Late Annual Report
FSF - Monthly Allotment/ Redemption Notice
1st July 2022 Morning Report
General Capital Releases 2022 Annual Report
Fonterra, NZX, EEX confirm GDT strategic partnership